Lifevantage Corp LFVN
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Lifevantage Corp (LFVN) is a healthcare company listed in the US with a market value of about $63M. In the twelve months to September 30, 2026 it had revenue of $172M and net income of $3M, a net margin of 1.6%.
Its overall Stock Analiz score is 3.0 out of 5 (average). The strongest part is financial health (5/5); the weakest is future growth (1/5).
Key numbers: a P/E of 23.7, a price to free cash flow of 7.2, 5-year revenue growth of -4% a year, a 5-year average ROIC of 11%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 23% below the current price.
About Lifevantage
Lifevantage is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $190M in 2015 to $183M in 2026, a decline of about 0.4% a year. It was profitable in 10 of the last 10 years in our data. It spends 1% of revenue on research and development.
Score: 3.0 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- 3-year free cash flow growth above 10% a year
- Profitable 5 years in a row
- ROE above 15%
- More cash than debt, or low debt to equity
- Positive free cash flow
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $172M | $183M | $229M | $200M | $213M | $206M | $220M | $233M | $226M | $203M | $199M |
| Net income | $3M | $5M | $10M | $3M | $3M | $3M | $13M | $12M | $7M | $6M | $2M |
| Free cash flow | $9M | $7M | $11M | $10M | $4M | $6M | $13M | $16M | $15M | $9M | $6M |
| EPS (diluted) | $0.21 | $0.40 | $0.75 | $0.23 | $0.20 | $0.24 | $0.90 | $0.79 | $0.50 | $0.41 | $0.11 |
| Net margin | 1.6% | 2.8% | 4.3% | 1.5% | 1.2% | 1.5% | 5.9% | 5.0% | 3.3% | 2.8% | 0.8% |
| ROIC | — | 11.7% | 21.1% | 7.4% | 5.7% | 10.7% | 24.0% | 35.4% | 27.6% | 22.7% | 11.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $6.50, 31% above the current price; targets range from $5.00 to $8.00; the consensus rating is “Buy”; expected EPS is $0.16 for the fiscal year ending June 30, 2027.
Frequently asked questions
What is Lifevantage’s P/E ratio?
About 23.7, based on the last twelve months of diluted earnings per share (forward P/E about 27.9).
Is Lifevantage stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 23% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Lifevantage pay a dividend?
Yes. The dividend yield is about 4.02%, and it has paid dividends for 5 years in our data.
Is Lifevantage a good stock to buy?
We do not give buy or sell advice. Lifevantage scores 3.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.